June 28, 2012
SAN BRUNO, Calif., June 28 — Numerate, Inc., a technology platform company that uses proprietary algorithms and the power of cloud computing to transform the drug design process, today announced integration of its platform with Google Compute Engine. Numerate collaborates with pharmaceutical and biotechnology partners to increase the speed and cost effectiveness of small molecule drug discovery for important diseases such as cancer, infectious disease and neurodegenerative diseases, including Parkinson's and Alzheimer's disease.
Numerate's in silico drug design platform features a set of proprietary algorithms that use machine learning to provide predictive models for molecular properties with accuracies comparable to laboratory testing. Used in conjunction with cloud computing, these algorithms enable Numerate scientists to search through spaces of billions of compounds to rapidly and efficiently identify those with the highest probability of activity against a specific target.
"The development of new medicines is greatly constrained by the complexities and serendipity of traditional drug discovery methods," said Nigel Duffy, Ph.D., chief technology officer at Numerate. "We have built a new computational process to remove this bottleneck by assuming a world with unconstrained access to computational resources. Capabilities like Google Compute Engine make that assumption a reality, allowing us to meet the needs of our growing list of pharmaceutical collaborators."
"Google Compute Engine is a flexible and easy-to-use platform offering a clean, simple API, a powerful security model, and the rapid provisioning of computational resources," said Brandon Allgood, Ph.D., Director of Computational Sciences at Numerate. "Rapid provisioning is critical for us as we elastically scale to thousands of cores in response to our partners' needs. Google Compute Engine excels in this regard. In fact, with a small amount of effort, we adapted our platform to Google Compute Engine and have already scaled to more than 10,000 cores."
Numerate, whose drug design system is built on Numatix, an elastically scalable dataflow processing platform for cloud computing, is one of several Google Compute Engine partners. "To help customers get the most out of our cloud platform products," explained Eric Morse, Head of Sales and Business Development for Google's cloud platform, "we work closely with technology companies that provide powerful complementary solutions integrated with our platform."
For more information on Numerate's drug design system, visit www.numerate.com, for more on Numatix visit www.numatix.net, and to learn more about the Google Compute Engine, visit http://cloud.google.compute.
Numerate is a privately held biotechnology company pioneering new computational methods for making the drug design process more data-driven, efficient and predictable. Numerate's in silico drug design platform combines proprietary algorithms and cloud computing with traditional medicinal chemistry approaches to address, in parallel, the factors that determine the success and failure of a drug candidate. Numerate applies this proprietary platform to design and develop small molecule therapeutics in collaboration with a variety of partners in the pharmaceutical, biotechnology, and academic fields. For more information, visit www.numerate.com (corporate site) and www.numerati.com (technical site) or follow Numatix on Twitter: @numatixData.
Source: Numerate, Inc.
Large-scale, worldwide scientific initiatives rely on some cloud-based system to both coordinate efforts and manage computational efforts at peak times that cannot be contained within the combined in-house HPC resources. Last week at Google I/O, Brookhaven National Lab’s Sergey Panitkin discussed the role of the Google Compute Engine in providing computational support to ATLAS, a detector of high-energy particles at the Large Hadron Collider (LHC).
Frank Ding, engineering analysis & technical computing manager at Simpson Strong-Tie, discussed the advantages of utilizing the cloud for occasional scientific computing, identified the obstacles to doing so, and proposed workarounds to some of those obstacles.
The private industry least likely to adopt public cloud services for data storage are financial institutions. Holding the most sensitive and heavily-regulated of data types, personal financial information, banks and similar institutions are mostly moving towards private cloud services – and doing so at great cost.
May 16, 2013 |
When it comes to cloud, long distances mean unacceptably high latencies. Researchers from the University of Bonn in Germany examined those latency issues of doing CFD modeling in the cloud by utilizing a common CFD and its utilization in HPC instance types including both CPU and GPU cores of Amazon EC2.
May 10, 2013 |
Australian visual effects company, Animal Logic, is considering a move to the public cloud.
May 10, 2013 |
Program provides cash awards up to $10,000 for the best open-source end-user applications deployed on 100G network.
05/10/2013 | Cleversafe, Cray, DDN, NetApp, & Panasas | From Wall Street to Hollywood, drug discovery to homeland security, companies and organizations of all sizes and stripes are coming face to face with the challenges – and opportunities – afforded by Big Data. Before anyone can utilize these extraordinary data repositories, however, they must first harness and manage their data stores, and do so utilizing technologies that underscore affordability, security, and scalability.
04/02/2012 | AMD | Developers today are just beginning to explore the potential of heterogeneous computing, but the potential for this new paradigm is huge. This brief article reviews how the technology might impact a range of application development areas, including client experiences and cloud-based data management. As platforms like OpenCL continue to evolve, the benefits of heterogeneous computing will become even more accessible. Use this quick article to jump-start your own thinking on heterogeneous computing.